Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT).
Takaaki KonumaMasamitsu YanadaSatoshi YamasakiYachiyo KuwatsukaTakahiro FukudaTakeshi KobayashiYukiyasu OzawaNaoyuki UchidaShuichi OtaTakumi HoshinoSatoshi TakahashiYoshinobu KandaYasunori UedaMinoko TakanashiJunya KandaTatsuo IchinoheYoshiko AtsutaShingo YanoPublished in: British journal of haematology (2018)
To evaluate the outcomes and prognostic factors following allogeneic haematopoietic cell transplantation (HCT) for adult acute myeloid leukaemia (AML) in second complete remission (CR2), we retrospectively analysed the Japanese registration data of 1080 adult AML patients in CR2 who had received allogeneic HCT. The probability of overall survival and the cumulative incidence of relapse at 3 years was 66% and 19%, respectively. In multivariate analysis, older age, poor cytogenetics and shorter duration of first complete remission were significantly associated with a higher overall mortality. Our data demonstrated the significant efficacy of allogeneic HCT for adult AML in CR2.
Keyphrases
- bone marrow
- stem cell transplantation
- acute myeloid leukemia
- prognostic factors
- cell therapy
- liver failure
- single cell
- respiratory failure
- end stage renal disease
- hematopoietic stem cell
- drug induced
- disease activity
- stem cells
- childhood cancer
- risk factors
- cardiovascular disease
- physical activity
- chronic kidney disease
- type diabetes
- machine learning
- electronic health record
- high dose
- immune response
- peritoneal dialysis
- low dose
- data analysis
- signaling pathway
- big data
- adipose tissue
- cell proliferation
- patient reported outcomes
- young adults
- systemic lupus erythematosus
- artificial intelligence
- deep learning
- glycemic control
- pi k akt